NCT01294774View on ClinicalTrials.gov

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Subacute Cutaneous Lupus Erythematosus
Interventions
DRUG

KRP203 - 1.2mg

DRUG

Placebo to KRP203 - 1.2 mg

Trial Locations (8)

16132

Novartis Investigative Site, Genova

44791

Novartis Investigative Site, Bochum

53100

Novartis Investigative Site, Siena

53105

Novartis Investigative Site, Bonn

60596

Novartis Investigative Site, Frankfurt am Main

72076

Novartis Investigative Site, Tübingen

161 21

Novartis Investigative Site, Athens

546 29

Novartis Investigative Site, Thessaloniki

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY